mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

• Status: Recruiting
• Trial end date: 2022-03-15

Summary

This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients with liver-dominant intrahepatic cholangiocarcinoma (ICC) that cannot be removed by surgery (unresectable). Drugs used in chemotherapy regimens, such as mFOLFIRINOX and mFOLFIRI (Oxaliplatin, Irinotecan, Fluorouracil, Folinic acid, Floxuridine) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Delivering chemotherapy via HAI (hepatic arterial infusion) can allow for liver-directed treatment while limiting toxic side effects typically seen with traditional chemotherapy.

• Phase: Phase 2

Details

• Lead Sponsor: OHSU Knight Cancer Institute
• Collaborator: Oregon Health and Science University
• Treatments: BB 1101; Calcium heparin; Deoxyuridine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Floxuridine; Fluorouracil; Folic Acid; Heparin; Irinotecan; Leucovorin; Levoleucovorin; Oxaliplatin